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Introduction: Voreloxin is an anticancer quinolone derivative that
intercalates DNA and inhibits topoisomerase II, causing double-
strand breaks in DNA, irreversible G2 arrest, and rapid onset of
apoptosis. Based on preclinical activity of voreloxin in chemoresis-
tant tumors, early phase I clinical activity, and a mechanism of
action similar to other topoisomerase II inhibitors such as the
anthracyclines and etoposide, this phase II trial was undertaken as
second-line treatment of small cell lung cancer (SCLC).
Methods: Patients with extensive stage SCLC previously treated
with one prior chemotherapy regimen were eligible. Patients with
chemotherapy-sensitive or chemotherapy-refractory disease were
considered as separate cohorts. Voreloxin (48 mg/m2) was admin-
istered on the first day of each 21-day cycle for up to six cycles. The
primary end point was objective response rate.
Results: Fifty-five patients were enrolled including 28 with refrac-
tory SCLC and 27 with sensitive SCLC; 47 were evaluable for
response. Three patients with sensitive SCLC had an objective
response, including one complete response and two partial responses
(11% response rate based on intent to treat). No patients in the
refractory cohort had a response. The primary grade 3 toxicity was
neutropenia.
Conclusion: Voreloxin has minimal activity in relapsed SCLC
when administered at 48 mg/m2 in a 3-week schedule.
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Despite a decline in incidence, small cell lung cancer(SCLC) remains a major public health issue, accounting
for more than 30,000 deaths annually in the United States.1
Most patients with SCLC will respond to a first-line chemo-
therapy regimen such as etoposide and cisplatin. Neverthe-
less, essentially all patients with extensive stage disease will
ultimately experience disease progression. Topotecan, the
only agent approved by the Food and Drug Administration
for relapsed SCLC, has limited efficacy. In a phase III trial
comparing oral topotecan with placebo in patients with re-
lapsed refractory or sensitive SCLC, the response rate was
7%, and median survival improved from 14 to 26 weeks.2
Clearly, the need is desperate for more effective therapies in
this patient population.
Voreloxin is a novel anticancer quinolone derivative
with a naphthyridine structure, which has been shown to
induce topoisomerase II-mediated DNA cleavage in vitro.3,4
Voreloxin is a DNA-damaging agent that causes double-
strand DNA breaks, irreversible G2 arrest, and rapid onset of
apoptosis.3 Voreloxin was extensively studied against an
array of human tumor cell lines and xenografts and showed
broad activity, particularly in drug-resistant tumors.5 For
example, the SCLC cell lines, SBC-3/ADM and SBC-3/ETP,
are highly resistant to several standard chemotherapy agents
such as etoposide, doxorubicin, and paclitaxel but remained
sensitive to voreloxin with an IC50 of 0.1 mol/liter (SBC-
3/ADM) and 0.4 mol/liter (SBC-3/ETP).5 Voreloxin has
also shown an excellent safety profile and hints of activity in
phase I clinical trials in patients with a variety of advanced
solid tumors. In two phase I dose-escalation trials, the dose-
limiting toxicity of voreloxin was febrile neutropenia, with
other adverse events limited mainly to mild nausea, vom-
iting, and fatigue.6 Half of the patients in the phase I trials
had stable disease, including those who were heavily
pretreated, and one patient with ovarian cancer had a
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partial response. Based on the preclinical activity in che-
motherapy-resistant tumors, the preliminary results in pa-
tients with advanced solid tumors, and a mechanism of
action similar to other topoisomerase II inhibitors such as
the anthracyclines and etoposide, this trial was undertaken
in second-line SCLC.
PATIENTS AND METHODS
Patients at least 18 years of age with measurable,
extensive stage SCLC previously treated with one chemo-
therapy regimen were eligible provided that first-line chemo-
therapy was completed at least 28 days previously. Palliative
radiation, if administered, must not have exceeded 25% of the
bone marrow and must have been completed at least 28 days
previously, with the exception of brain radiation that could
have been completed 14 days earlier. Eastern Cooperative
Oncology Group performance status had to be 0, 1, or 2.
Exclusion criteria included uncontrolled brain metastases; a
history of myocardial infarction, cerebrovascular event, or
transient ischemic attack within 6 months; history of deep
venous thrombosis or pulmonary embolism within 28 days;
or other active malignancy in the last 12 months. Required
laboratory parameters included an absolute neutrophil
count  1.5  109/liter; platelet count  100  109/liter;
hemoglobin  9 g/dl; calculated or measured creatinine
clearance  50 ml/min or serum creatinine  1.5 times the
institution’s upper limit of normal (ULN); aspartate transam-
inase and alanine aminotransferase  ULN (except  5 
ULN if liver metastases); and total bilirubin  1.5  ULN.
Individual institutional review boards at participating institu-
tions reviewed the protocol and informed consent documents,
and all patients signed informed consent. The trial was
registered at www.clinicaltrials.gov as NCT00298896.
Pretreatment evaluations included a complete blood
count, chemistry panel, urinalysis, pregnancy test if appro-
priate, electrocardiogram, computed tomography imaging of
sites of disease, and brain imaging. Voreloxin was adminis-
tered at a dose of 48 mg/m2 by short intravenous infusion
over 10 minutes once every 3 weeks for up to six cycles. This
dose was chosen based on the results of a phase I trial.6 An
assessment of adverse events, a physical examination, routine
blood work, and an urinalysis were performed before each
treatment. Computed tomography scans were obtained after
every two cycles to assess response.
The primary end point was objective response rate,
determined using RECIST.7 Secondary end points included
best overall response, duration of response, progression-free
survival, time to progression, tumor size, and overall survival.
Patients with sensitive SCLC (defined as response to
initial chemotherapy lasting 90 days) and patients with
refractory SCLC (defined as having no response to first-line
chemotherapy or who responded and then experienced dis-
ease progression within 90 days) were considered as separate
cohorts, and a Fleming two-stage design was used for each
cohort separately.8 For the sensitive stratum, the null hypoth-
esis assumed that the true response rate was 11%, and the
alternative hypothesis suggested that the true response rate
was 30%. At least two responses were required among the
first 20 patients to proceed to the second stage of enrollment.
Initially, another 20 patients were then planned for enroll-
ment in the second stage. An amendment to the protocol later
expanded the second stage to 40 patients to reduce the
confidence intervals around the response rate.
For the refractory stratum, the null hypothesis assumed
that the true response rate was 4%, and the alternative
hypothesis suggested that the true response rate was 18%.
At least one response was required among the first 20 patients
to proceed to the second stage of enrollment. In stage 2, an
additional 20 patients were to be enrolled, and at least five
responses were required to deem the drug effective.
The pharmacokinetic (PK) profile of voreloxin was
evaluated at three institutions. Blood samples for PK analysis
were collected after the first dose of voreloxin at the end of
the infusion (5 minutes) and at 2, 6, 24, and 72 hours
postdose. Plasma voreloxin concentrations were measured
using a liquid chromatography atmospheric pressure ioniza-
tion tandem/mass spectrometry method, with a lower limit of
quantitation of 2 ng/ml. The analytic method for determining
voreloxin concentrations has been described previously.9
RESULTS
Between March 2006 and August 2007, 13 study cen-
ters enrolled 55 patients, including 27 with sensitive SCLC
and 28 with refractory SCLC. Patient characteristics were
similar between cohorts (Table 1). The median age was 59
years, 55% were men, and most patients had an Eastern
Cooperative Oncology Group performance status of 0 (24%)
TABLE 1. Baseline Patient Characteristics
Characteristics
Sensitive
(N  28)
Refractory
(N  27)
Total
(N  55)
Median age (yr) 60 59 59
Male (%) 46 63 55
ECOG performance status (%)
0 29 19 24
1 64 67 66
2 7 7 7
Unknown 0 7 4
Stage at diagnosis (%)
Limited 50 7 29
Extensive 50 93 71
Prior chemotherapy (%)
EP 86 93 89
EP  bevacizumab 4 0 2
EP  tirapazamine 4 0 2
EP  topotecan 4 0 2
EP  paclitaxel 0 4 2
Irinotecan/cisplatin/bevacizumab 4 4 4
Prior radiation therapy (%)
Thoracic 57 30 44
Whole brain 71 33 53
Other 0 4 2
ECOG, Eastern Cooperative Oncology Group; EP, etoposide  cisplatin or carbo-
platin.
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or 1 (66%). Ninety-six percent received an etoposide/plati-
num-based regimen as first-line therapy.
Forty-seven patients were evaluable for response (Ta-
ble 2); one patient was not treated, and seven had no fol-
low-up imaging after starting therapy. Three patients with
sensitive SCLC had an objective tumor response (one com-
plete response and two partial responses) for a response rate
of 11% in the sensitive SCLC cohort and 6% overall by intent
to treat. Thirteen patients (24%) overall had stable disease.
The Data Monitoring Committee convened after enrollment
was complete for the initial stage. The refractory stratum was
closed to enrollment due to the lack of objective responses.
Although the sensitive stratum continued to enroll patients,
the sponsor ultimately closed the study to enrollment early, as
the response rate was unlikely to be superior to other avail-
able therapies used to treat SCLC in the second-line setting,
including topotecan. No survival data were collected due to
the early study closure.
The most common toxicities (20% of patients), re-
gardless of grade or attribution to treatment, were fatigue
(72%), nausea (54%), neutropenia (37%), constipation
(30%), vomiting (24%), back pain (22%), and dyspnea
(22%). Sixty-three percent of patients experienced grade 3 or
greater toxicities; the most common were neutropenia (28%),
fatigue (9%), and back pain (7%). Four patients (7%) devel-
oped febrile neutropenia. Thirteen patients died on study, all
related to progressive disease except one patient with sudden
death and another in a fatal automobile accident.
Blood samples for PK analysis were collected from 10
patients (six sensitive and four refractory). After a short
intravenous infusion, plasma concentrations declined in a
biphasic manner; the decline consisted of a rapid distribution
phase followed by a prolonged elimination phase with a mean
terminal half-life of 19.1 hours. The mean total body clear-
ance was 1.78 liter/h/m2 and mean volume of distribution at
steady state was 43.74 liter/m2.
DISCUSSION
Based on the preclinical activity in chemoresistant
tumor models and early phase I clinical activity, voreloxin
seemed appropriate for study in SCLC. On relapse after
first-line chemotherapy, SCLC is extremely challenging to
treat, as evidenced by the low response rate and minimal
improvement in survival with currently available agents such
as topotecan. Furthermore, voreloxin damages DNA through
its inhibition of topoisomerase II,3 a mechanism of action
common to other drugs used to treat SCLC, such as etopo-
side. Nonetheless, the minimal activity (11% in sensitive
SCLC) in our study is comparable with responses obtained
with other currently available therapies and thus represents no
improvement.
The toxicity and PK profiles for voreloxin in this study
are consistent with the results of previous phase I clinical
studies in patients with solid tumors.6 Additional phase II
experience with voreloxin in platinum-resistant ovarian can-
cer indicates better clinical activity with a dosing regimen of
60 mg/m2 every 4 weeks10; thus, the dose regimen studied in
SCLC may not be optimal. Nevertheless, given the low
response rate, further exploration of voreloxin in the treat-
ment of SCLC is not planned. Voreloxin is currently being
studied as a single agent and in combination with cytarabine
in acute myelogenous leukemia.
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TABLE 2. Summary of Response Assessment per RECIST
Based on Intent to Treat
Sensitive
(N  28),
No. (%)
Refractory
(N  27),
No. (%)
Total
(N  55),
No. (%)
Complete response 1 (4) 0 (0) 1 (2)
Partial response 2 (7) 0 (0) 2 (4)
Stable disease 8 (29) 5 (19) 13 (24)
Progression 13 (46) 18 (67) 31 (56)
Not evaluable 4 (14) 4 (15) 8 (15)
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